Synergy Pharmaceuticals Inc

Type: Company
Name: Synergy Pharmaceuticals Inc
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape

Anacor Pharmaceuticals, Inc. ( ANAC ) was a big mover last session, as the company saw its shares surge nearly 7% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This stock, ... [Published Zacks.com - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Synergy Pharmaceuticals Progresses with Mid-Stage Candidate

Synergy Pharmaceuticals Inc. ( SGYP - Snapshot Report ) completed patient enrollment for its phase II study on SP-333 being developed for the treatment of patients suffering from opioid-induced constipation (OIC).The phase dose-ranging II study is evaluating ... [Published Zacks.com - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Patient enrollment for Synergy OIC drug trial complete

18:59 ET | About: Synergy Pharmaceuticals, Inc. (SGYP)Patient enrollment in the 260-patient Phase 2 clinical trial evaluating Synergy Pharmaceuticals' (SGYP -5.7%) uroguanylin analog SP-333 as a treatment for opioid-induced constipation (OIC) is complete. ... [Published Seeking Alpha - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 3 reports

Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation

First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Synergy Pharmaceuticals Sees Significant Increase in Short Interest (SGYP)

Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) were the target of a large increase in short interest in June. As of June 30th, there was short interest totalling 16,195,779 shares, an increase of 17.1% from the June 13th total of 13,832,018 shares, ARN ... [Published American Banking News - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 8 reports

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Details Category: Proteins and Peptides Published on Monday, 14 July 2014 17:43 Hits: 11 Top-line data for the first pivotal phase 3 CIC trial expected in the second quarter 2015NEW YORK, NY, USA I July 14, 2014 I Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ... [Published PipelineReview - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape

La Jolla Pharmaceutical Co. ( LJPC ) was a big mover last session, as the company saw its shares surge 19% on the day. This massive rally can be attributable to solid volume with far more shares changing hands than in a normal session. This broke the ... [Published Zacks.com - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4%

TherapeuticsMD, Inc. ( TXMD ) saw a big move last session, as the company’s shares fell by over 8% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This stock, trading at a volatile range ... [Published Yahoo! Finance - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Synergy Pharmaceuticals' Plecanatide to Move into Phase III

Synergy Pharmaceuticals Inc. ( SGYP ) intends to start a pivotal phase III study on its lead pipeline candidate, plecanatide, in the fourth quarter of 2014 after successfully completing an end-of-phase II meeting with the FDA.Plecanatide is being developed ... [Published Yahoo! Finance - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Tetraphase Pharmaceuticals (TTPH) Crumbles: Stock Tanks by 1…

Tetraphase Pharmaceuticals, Inc. ( TTPH - Snapshot Report ) saw a big move last session, as the company’s shares fell by over 16% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This ... [Published Zacks.com - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 5 reports

Synergy Pharmaceuticals Inc announces successful end-of-phase 2 meeting with FDA for plecanatide in irritable bowel syndrome with constipation

Synergy Pharmaceuticals Inc:Says pivotal phase 3 IBS-C Program to be initiated in the fourth quarter.Completes an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on lead drug plecanatide for the treatment of irritable bowel syndrome ... [Published Reuters - Jul 08 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 2 reports

Jazz Pharmaceuticals Public Limited Company (JAZZ)...

Jazz Pharmaceuticals Public Limited Company ( JAZZ ) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the ... [Published Nasdaq - Jul 03 2014]

Quotes

...plan to fully develop FV-100 as a novel treatment for shingles," said James Sapirstein, Chief Executive Officer of ContraVir Pharmaceuticals. "Bill's experience in executing the finance function and contributing to the strategic planning and operations of emerging biopharmaceutical companies is essential, and will help ContraVir achieve its objective to become a leader in the antiviral drug segment."
...Gary S Jacob, Chairman and CEO of Synergy. "The pivotal phase 3 IBS-C trials will include both 3.0 mg and 6.0 mg plecanatide, which are consistent with the doses currently being evaluated in our phase 3 chronic idiopathic constipation (CIC) program. Plecanatide has demonstrated a clinical dose-response for efficacy with an excellent tolerability profile that is observed across trials. This is an important advantage as we look to bring two doses to market in both indications and provide physicians with options for addressing individual patient needs."
...Allergan said the offer by Valeant Pharmaceuticals and William Ackman "substantially undervalues Allergan and is not in the best interests of the company and its stockholders." ( http://r.reuters.com/xyg39v )

More Content

All (105) | News (64) | Reports (0) | Blogs (41) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Synergy completes patient enrollment for Phase ... [Published Individual.com - Jul 25 2014]
Anacor's Kerydin to Be Commercialized by Sandoz... [Published Nasdaq - Jul 22 2014]
Jazz Pharmaceuticals/Concert Pharmaceuticals St... [Published Yahoo! Finance - Jul 22 2014]
Anacor's Kerydin to Be Commercialized by Sandoz... [Published Yahoo! Finance - Jul 22 2014]
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: S... [Published Zacks.com - Jul 22 2014]
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: S... [Published Yahoo! Finance - Jul 22 2014]
Astellas Up on Pipeline Update, Oncology in Foc... [Published Zacks.com - Jul 21 2014]
Astellas Up on Pipeline Update, Oncology in Foc... [Published Yahoo! Finance - Jul 21 2014]
Synergy closes patient enrollment in Phase II t... [Published PBR - News - Jul 21 2014]
Synergy Pharmaceuticals Progresses with Mid-Sta... [Published Zacks.com - Jul 18 2014]
Salix-Pharming's Ruconest Gets FDA Nod for HAE [Published Zacks.com - Jul 18 2014]
Patient enrollment for Synergy OIC drug trial c... [Published Seeking Alpha - Jul 18 2014]
Astellas' Isavuconazole Gets QIDP for Invasive ... [Published Zacks.com - Jul 17 2014]
Synergy Pharmaceuticals Completes Patient Enrol... [Published Digital Journal - Jul 17 2014]
Synergy Pharmaceuticals Completes Patient Enrol... [Published Business Wire Health News - Jul 17 2014]
Synergy Pharmaceuticals Completes Patient Enrol... [Published Benzinga.com - Jul 17 2014]
Astellas Up on Pipeline Update, Oncology in Foc... [Published Zacks.com - Jul 16 2014]
Astellas Up on Pipeline Update, Oncology in Focus [Published Yahoo! Finance - Jul 16 2014]
Synergy Pharmaceuticals Sees Significant Increa... [Published American Banking News - Jul 16 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published PipelineReview - Jul 14 2014]
Zafgen's Beloranib Gets Orphan Drug Status in t... [Published Zacks.com - Jul 14 2014]
Strength Seen in La Jolla Pharmaceutical Co. (L... [Published Zacks.com - Jul 14 2014]
Sector Update: Health Care [Published Nasdaq - Jul 14 2014]
Synergy Pharmaceuticals enrolls CIC patient in ... [Published Individual.com - Jul 14 2014]
Synergy reaches halfway point in Phase 3 CIC trial [Published Seeking Alpha - Jul 14 2014]
Strength Seen in La Jolla Pharmaceutical Co. (L... [Published Yahoo! Finance - Jul 14 2014]
Synergy Pharma Reaches Halfway Mark For 1st Piv... [Published RTTNews.com - Jul 14 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Digital Journal - Jul 14 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Myrtle Beach Sun News - Jul 14 2014]
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Science: Science News - Jul 14 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Synergy closes patient enrollment in Phase II t... [Published PBR - News - Jul 21 2014]
US-based Synergy Pharmaceuticals has completed patient enrollment in its Phase II trial of SP-333, its next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC). ...
Synergy Pharmaceuticals Completes Patient Enrol... [Published Business Wire Health News - Jul 17 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation ...
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Science: Science News - Jul 14 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ...
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Health News - Jul 14 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ...
Synergy Pharmaceuticals Announces Successful En... [Published Business Wire Health News - Jul 08 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Plecanatide in Irritable Bowel Syndrome with Constipation ...
1 2 3 4 5 6 7 8 9
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.